CORBF vs. FLGT, CDNA, CSTL, AGL, INNV, AUNA, SBC, TALK, PSNL, and EHAB
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Fulgent Genetics (FLGT), CareDx (CDNA), Castle Biosciences (CSTL), Agilon Health (AGL), InnovAge (INNV), Auna (AUNA), SBC Medical Group (SBC), Talkspace (TALK), Personalis (PSNL), and Enhabit (EHAB). These companies are all part of the "healthcare" industry.
Global Cord Blood vs. Its Competitors
Fulgent Genetics (NASDAQ:FLGT) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.
48.1% of Fulgent Genetics shares are held by institutional investors. 31.8% of Fulgent Genetics shares are held by insiders. Comparatively, 0.5% of Global Cord Blood shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Fulgent Genetics had 5 more articles in the media than Global Cord Blood. MarketBeat recorded 5 mentions for Fulgent Genetics and 0 mentions for Global Cord Blood. Fulgent Genetics' average media sentiment score of 0.68 beat Global Cord Blood's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the media.
Fulgent Genetics currently has a consensus target price of $25.33, indicating a potential upside of 14.99%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Global Cord Blood.
Global Cord Blood has a net margin of 0.00% compared to Fulgent Genetics' net margin of -16.83%. Global Cord Blood's return on equity of 0.00% beat Fulgent Genetics' return on equity.
Fulgent Genetics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500.
Global Cord Blood has lower revenue, but higher earnings than Fulgent Genetics.
Summary
Fulgent Genetics beats Global Cord Blood on 10 of the 14 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
This page (NYSE:CORBF) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access